FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

(2016) Hong Jiang et al.   NATURE MEDICINE

From bench to bedside a comprehensive review of pancreatic cancer immunotherapy

(2016) Paul R. Kunk et al.   Journal for ImmunoTherapy of Cancer

Nuclear FAK Controls Chemokine Transcription, Tregs, and Evasion of Anti-tumor Immunity

(2015) Alan Serrels et al.   CELL

FAK signaling in human cancer as a target for therapeutics

(2015) Brian Y. Lee et al.   PHARMACOLOGY & THERAPEUTICS

Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy

(2014) Bernardo Tavora et al.   NATURE

Merlin Deficiency Predicts FAK Inhibitor Sensitivity: A Synthetic Lethal Relationship

(2014) I. M. Shapiro et al.   Science Translational Medicine

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment

(2011) J. B. Stokes et al.   MOLECULAR CANCER THERAPEUTICS